Streetbeat News

ENGN

enGene Holdings Inc. Common Stock

https://www.engene.com

Industry

Biotechnology

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

enGene has appointed Ron Cooper as the new Chief Executive Officer, effective July 22, 2024, succeeding Jason Hanson. Additionally, Dr. Raj Pruthi has been promoted to Chief Medical Officer.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:35 am

EnGene Holdings Inc. (NASDAQ:ENGN) shares are trading lower after reporting a significant increase in net loss for Q2 2024, driven by higher operating expenses. The company also announced strategic developments, including the expansion of its LEGEND study and key leadership hires.

Portfolio Pulse from Vaishali Prayag

June 14, 2024 | 6:26 pm

EnGene Holdings shares are trading lower after the company reported Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 4:32 pm

enGene reported a Q2 EPS loss of $0.38, with a net loss of $15.0 million for the quarter ending April 30, 2024. The company exited the quarter with $264.8 million in cash and equivalents. The increased net loss is mainly due to higher operating expenses, partially offset by net interest income.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:06 am

enGene Holdings Inc. (NASDAQ:ENGN) announced its participation in the American Urology Association 2024 Annual Meeting to present details of its Phase 1/2 LEGEND study of EG-70, a non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer. The presentation will highlight EG-70's design, addressing challenges of other treatments, and share promising initial efficacy and safety data. Complete response rates in the Phase 1 subgroup showed 70% and 60% at three and six months, respectively, indicating potential for durable remissions without significant quality of life impairment.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 9:05 pm

Wells Fargo analyst Yanan Zhu has initiated coverage on enGene Holdings (NASDAQ:ENGN) with an Overweight rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 1:27 pm

Guggenheim analyst Manuel Navas initiates coverage on enGene Holdings (NASDAQ:ENGN) with a Buy rating and a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:46 am

UBS analyst Colin Bristow initiates coverage on enGene Holdings (NASDAQ:ENGN) with a Buy rating and a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 3:06 pm

enGene Holdings reported a Q1 net loss of $10.7 million, or $0.46 per share. The company also closed a $200 million oversubscribed private financing, extending its cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:41 pm

Morgan Stanley has initiated coverage on enGene Holdings (NASDAQ:ENGN) with an Overweight rating and set a price target of $40. This move by a prominent analyst could influence investor sentiment and potentially impact ENGN's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 2:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.